Overview
RetinAI Medical provides an AI-powered healthcare data platform that harmonizes and analyzes unstructured medical data from formats like DICOM and proprietary systems. It helps medical professionals, researchers, and healthcare organizations manage, access, and analyze data to reveal insights about disease progression and treatment outcomes. The platform supports data collection, processing, visualization, and global collaboration through a subscription model and partnerships with clinics and research institutions. Its goal is to help healthcare providers make data-driven decisions that improve patient outcomes.
Work here?Claim your company
About RetinAI Medical
Industries
Company Size
11-50
Company Stage
Series B
Total Funding
$16.7M
Headquarters
Bern, Switzerland
Founded
2016
Get referred to RetinAI Medical
See people who can refer or advise you
Simplify's Take
What believers are saying
- LuxIA won CE-MDR Class IIb certification on April 30, 2025, expanding regulated use.
- June 24, 2024 MDR certification covered four devices, strengthening RetinAI's compliance moat.
- EssilorLuxottica's October 15, 2025 acquisition opens hospital, pharma, and retail eye-care channels.
What critics are saying
- Swiss study in April 2026 found server-hosting, anonymization, and interoperability barriers.
- RetinAI Discovery's automated AI modules remain research-use-only in the United States, limiting adoption.
- By 2027, EssilorLuxottica can absorb RetinAI into its stack, killing standalone identity.
What makes RetinAI Medical unique
- RetinAI Discovery holds FDA 510(k) clearance and CE marking, rare in ophthalmic AI.
- Its platform unifies OCT, fundus, and biomarker data for clinics and pharma partners.
- EssilorLuxottica acquired RetinAI on October 15, 2025, giving global distribution leverage.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$16.7M
Below
Industry Average
Funded Over
7 Rounds
Industry standards
Growth & Insights and Company News
6 month growth
-2%1 year growth
-4%2 year growth
2%EssilorLuxottica has acquired Ikerian, operating under the RetinAI brand, to enhance its med-tech strategy by integrating advanced AI and data management technologies for the optical sector. RetinAI's platform, RetinAI Discovery, approved by the FDA and CE certified, uses AI to monitor eye diseases, enabling timely diagnoses and targeted interventions. This marks EssilorLuxottica's fourth acquisition in 2025, following Automation Robotics, PUcore, and Optegra.
EssilorLuxottica acquires RetinAI, accelerating transformative AI and data-powered eye health solutions. October 15, 2025 12:45 ET | Source: EssilorLuxottica EssilorLuxottica acquires RetinAI, accelerating transformative AI and data-powered eye health solutions Paris, France (15 October 2025) - EssilorLuxottica announces the acquisition of Ikerian AG, a health technology company, operating under the RetinAI brand, specializing in AI and data management in eyecare. This move reinforces the Group's med-tech journey, adding advanced software powered by machine learning and computer vision. These solutions streamline clinical, research and pharmaceutical workflows, and deliver actionable AI-driven insights that empower healthcare professionals and enhance patient care. RetinAI develops advanced tools to collect, process and grade large-scale retinal images and biomarker datasets. Its FDA cleared 510(k) and CE-marked flagship platform, RetinAI Discovery, applies AI models to support diagnosis and monitoring of disease progression - including age-related macular degeneration (AMD), glaucoma and diabetic retinopathy - enabling more accurate and timely decisions in managing eye diseases. At the same time, RetinAI partners with pharmaceutical companies and research organizations that leverage proprietary real-world evidence to accelerate clinical studies and drug development. "In the past year alone, we've made several bold moves in med-tech, all with the goal of building the most comprehensive, digitally enabled patient journey. RetinAI will add incredible value to an ecosystem that already includes comprehensive eyecare, advanced diagnostics, therapeutic innovation and surgical excellence. Leveraging its AI-powered analytics, we can turn clinical data into insights that enable faster, more accurate diagnoses and more effective disease monitoring. We are ushering in a new era of healthcare, and it will be transformative for patients everywhere", commented Francesco Milleri, Chairman and CEO at EssilorLuxottica. "Joining EssilorLuxottica marks a defining moment in our journey. This acquisition opens an exciting new chapter for our team and technology. From the start, we've believed in the power of data and AI to transform patient care. With EssilorLuxottica's global reach and deep commitment to innovation, we can now bring that vision to life at an entirely new scale and level of positive impact. Together, we'll shape how technology drives better healthcare, sharper vision, and improved outcomes for patients", said Carlos Ciller, PhD, Chairman and CEO of RetinAI/Ikerian AG.
Bern, Switzerland and Madrid, Spain — 30 April 2025 — RetinAI US Inc. (RetinAI) and Fundación Ver Salud (FVS) are pleased to jointly announce that LuxIA®, their co-developed innovative AI algorithm for Diabetic Retinopathy (DR) screening, has successfully received CE-MDR certification as a Class IIb medical device under the European Union Medical Device Regulation (EU MDR 2017/745). The certification was granted through Ikerian AG, RetinAI’s parent company.LuxIA is designed to screen adult diabetic patients for more-than-mild diabetic retinopathy (mtmDR). This indication for use provides critical support for ophthalmologists, general practitioners and trained healthcare professionals across the European Union to achieve an earlier diagnosis of mtmDR, a vision-threatening eye disease. This new certification demonstrates the strong collaboration between FVS and RetinAI, emphasizing both entities’ commitment to deliver AI-driven tools that meet stringent regulatory standards and significantly enhance patient management and clinical outcomes.The device is indicated for processing digital 45-degree colour fundus images from NW200, NW400 or equivalent Topcon cameras, ensuring seamless placement into existing clinical workflows. Together with RetinAI’s existing portfolio of AI-based OCT analysis solutions, LuxIA complements a comprehensive suite of clinically validated, CE-certified AI modules focused on ophthalmology.Dr
The Venture Kick, Venture Leader, and TOP 100 startup Ikerian has secured USD 8 million in the first tranche of its Series B funding to advance its RetinAI Discovery® platform. This investment will enhance its AI technology for large-scale data management, improve healthcare data workflows, and integrate AI-driven patient pre-screening. Additionally, it will support Ikerian's expansion into new therapeutic areas, including neurodegenerative disorders, vascular conditions, and rare diseases.
Swiss Ikerian AG's US-subsidiary, RetinAI U.S. Inc. has announced the first close of an CHF6.73m Series B financing with new and existing investors to advance its AI-based image analysis platform alongside a strategic partnership.
RetinAI Medical is Hiring for 5 Jobs on Simplify!
Find jobs on Simplify and start your career today
About RetinAI Medical
Industries
Company Size
11-50
Company Stage
Series B
Total Funding
$16.7M
Headquarters
Bern, Switzerland
Founded
2016
RetinAI Medical is Hiring for 5 Jobs on Simplify!
Find jobs on Simplify and start your career today